CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
This Quarter Return
+14.98%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$787M
AUM Growth
+$787M
(+53%)
Cap. Flow
+$228M
Cap. Flow
% of AUM
29.03%
Top 10 Holdings %
Top 10 Hldgs %
30.43%
Holding
459
New
34
Increased
332
Reduced
39
Closed
19
Top Buys
| 1 |
Microsoft
MSFT
|
$18.2M |
| 2 |
NVIDIA
NVDA
|
$11.9M |
| 3 |
Netflix
NFLX
|
$9.94M |
| 4 |
Amazon
AMZN
|
$7.89M |
| 5 |
Meta Platforms (Facebook)
META
|
$7.84M |
Top Sells
| 1 |
Vanguard World Funds Extended Duration ETF
EDV
|
$3.64M |
| 2 |
Alibaba
BABA
|
$2.59M |
| 3 |
XYZ
Block, Inc.
XYZ
|
$2.4M |
| 4 |
Intel
INTC
|
$2.07M |
| 5 |
Coca-Cola
KO
|
$1.91M |
Sector Composition
| 1 | Technology | 37.36% |
| 2 | Healthcare | 29.98% |
| 3 | Consumer Discretionary | 13.6% |
| 4 | Communication Services | 8.97% |
| 5 | Financials | 3.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
351
Galapagos
GLPG
$2.05B
| $121K | 0.02% |
3,769
+1,504
| +66% | +$48.4K |
|
352
OmniAb
OABI
$227M
| $121K | 0.02% |
22,321
+8,871
| +66% | +$48.1K |
|
353
Olema Pharmaceuticals
OLMA
$444M
| $120K | 0.02% |
10,562
+4,221
| +67% | +$47.8K |
|
354
Castle Biosciences
CSTL
$702M
| $117K | 0.01% |
5,297
+2,187
| +70% | +$48.4K |
|
355
MongoDB
MDB
$26B
| $117K | 0.01% |
326
+185
| +131% | +$66.3K |
|
356
Phathom Pharmaceuticals
PHAT
$841M
| $117K | 0.01% |
10,989
+4,363
| +66% | +$46.3K |
|
357
Editas Medicine
EDIT
$222M
| $117K | 0.01% |
15,713
+6,263
| +66% | +$46.5K |
|
358
Amphenol
APH
$133B
| $116K | 0.01% |
1,000
| – | – |
|
359
AnaptysBio
ANAB
$577M
| $115K | 0.01% |
5,123
+2,051
| +67% | +$46.2K |
|
360
Take-Two Interactive
TTWO
$44.4B
| $114K | 0.01% |
769
+430
| +127% | +$63.9K |
|
361
Tourmaline Bio
TRML
$606M
| $113K | 0.01% |
4,939
+2,582
| +110% | +$59.1K |
|
362
Travere Therapeutics
TVTX
$1.62B
| $113K | 0.01% |
14,652
+5,962
| +69% | +$46K |
|
363
Lexicon Pharmaceuticals
LXRX
$407M
| $113K | 0.01% |
46,930
+18,601
| +66% | +$44.6K |
|
364
Fulcrum Therapeutics
FULC
$347M
| $112K | 0.01% |
11,916
+4,766
| +67% | +$45K |
|
365
Alector
ALEC
$262M
| $111K | 0.01% |
18,403
+8,670
| +89% | +$52.2K |
|
366
Lyell Immunopharma
LYEL
$219M
| $109K | 0.01% |
48,855
+19,718
| +68% | +$44K |
|
367
ALX Oncology
ALXO
$55.2M
| $107K | 0.01% |
9,587
+3,825
| +66% | +$42.6K |
|
|
PETQ
368
DELISTED
PetIQ, Inc. Class A Common Stock
PETQ
| $103K | 0.01% |
5,643
+2,271
| +67% | +$41.5K |
|
369
Taysha Gene Therapies
TSHA
$775M
| $103K | 0.01% |
35,908
+14,286
| +66% | +$41K |
|
370
Biomea Fusion
BMEA
$121M
| $103K | 0.01% |
6,862
+2,731
| +66% | +$40.8K |
|
371
Mineralys Therapeutics
MLYS
$1.91B
| $102K | 0.01% |
7,931
+3,181
| +67% | +$41.1K |
|
372
TJX Companies
TJX
$155B
| $101K | 0.01% |
1,000
| – | – |
|
|
HSAI
373
Hesai Group
HSAI
$3.31B
| $101K | 0.01% |
20,000
| – | – |
|
374
HUTCHMED
HCM
$2.63B
| $99.7K | 0.01% |
5,933
+2,340
| +65% | +$39.3K |
|
375
Voyager Therapeutics
VYGR
$199M
| $96.9K | 0.01% |
10,404
+5,311
| +104% | +$49.4K |
|